Genomic Health, Inc. was a company focusing on genetic research specifically in cancer detection, based out of Redwood City, California. The company developed Oncotype DX, a genomic assay that quantified the likelihood of breast cancer recurrence.

Randy Scott

Genomic Health, Inc.

American Esoteric Laboratories (AEL) is a laboratory providing diagnostic testing services. It is self-described as being accredited by the College of American Pathologists and licensed by the State of Tennessee.

American Esoteric Laboratories (AEL)

Ortho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company is also involved in the provision of contract manufacturing and orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. Ortho Clinical Diagnostics Holdings plc was founded in 1939 and is headquartered in Raritan, New Jersey.

Ortho Clinical Diagnostics Holdings plc

Spekle Solutions specializes in shaping market access and commercial strategies for life sciences. The company uses advanced analytical techniques and technology to provide customized solutions and insights.

Spekle Solutions

About Genomic Health 
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care by addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ® Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 750,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the recently launched Oncotype SEQ® Liquid Select™ test. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth,  Facebook, YouTube and LinkedIn.

About Oncotype DX®
The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX Breast Recurrence Score®, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the Oncotype DX Breast DCIS Score™ predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. In prostate cancer, the Oncotype DX Genomic Prostate Score™ predicts disease aggressiveness and further clarifies the current and future risk of the cancer prior to treatment intervention. With more than 750,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeIQ.com, www.MyBreastCancerTreatment.org or www.MyProstateCancerTreatment.org.

Invitae

Genomic Health

Cancer, whether it be breast cancer or another form, touches just about everyone, including Kim Popovits, Chairman, CEO and President at Genomic Health, Inc. Ms. Popovits talks about her inspiration for getting involved with personalized medicine in the treatment of cancer. https://lnkd.in/eyvQx_2

Metric
Company Name	Genomic Health, Inc.	American Esoteric Laboratories (AEL)	Ortho Clinical Diagnostics Holdings plc	Spekle Solutions
Symbol			OCDX
MSH ID	COM:GENOMICHEALTH	COM:AEL	COM:ORTHOCLINICALDIAGNOSTICS	COM:SPEKLESOLUTIONS
Market	PRIVATE	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare	Commercial & Professional Services
Industry	Genomics	Medical Diagnostics	Medical - Diagnostics & Research	Consulting
Country	US	US	US	US
Stage
Employee Count	336		4.80K
Website	genomichealth.com	ael.com	orthoclinicaldiagnostics.com	speklesolutions.com
LinkedIn	genomic-health
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	89
Web Traffic Growth	1.01
Valuation
Raised Capital

Metric
Revenue			2.04B
Revenue (LTM)
Revenue (NTM)
Gross Profit			1.04B
EBITDA			253.40M
Operating Income			120M
Net Income			-54.30M
EPS			-0.23
Diluted EPS			-0.22
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.51
Operating Profit Margin			0.06
EBITDA Margin			0.12
Net Profit Margin			-0.03
Return on Equity			0.18
Return on Assets			-0.02
Return on Capital Employed			0.04

COM:GENOMICHEALTH

Genomic Health, Inc.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			-76.49
P/B Ratio			10.12
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple			-7.66

Metric
Days Sales Outstanding			45.96
Days Payables Outstanding			65.62
Days Inventory Outstanding			110.72
Operating Cycle			156.67
Cash Conversion Cycle			91.05
Asset Turnover			0.61

Metric
Operating Cash Flow			286.60M
Free Cash Flow			286.60M
Cash Flow to Debt			0.13
Operating Cash Flow/Sales			0.14
Free Cash Flow Yield

Metric
Cash & Equivalents			309.70M
Accounts Receivable
Inventory			305.40M
Goodwill			573.60M
Debt to Capitalization			0.85
Debt to Assets			0.67
Current Ratio			1.75
Quick Ratio			0.98

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue			0.06
SG&A to Revenue